Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells

Diana Hanekamp; Lok Lam Ngai; Jeroen Jwm Janssen; Arjan A van de Loosdrecht; Gert J Ossenkoppele; Jacqueline Cloos

doi:10.1182/blood.2020007150

Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen Jwm Janssen, Arjan A van de Loosdrecht, Gert J Ossenkoppele, Jacqueline Cloos

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Journal	Blood
DOIs	https://doi.org/10.1182/blood.2020007150
Publication status	E-pub ahead of print - 10 Nov 2020

Access to Document

10.1182/blood.2020007150

Cite this

@article{baacdf73516347019178604cd7f4456f,

title = "Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells",

author = "Diana Hanekamp and Ngai, {Lok Lam} and Janssen, {Jeroen Jwm} and {van de Loosdrecht}, {Arjan A} and Ossenkoppele, {Gert J} and Jacqueline Cloos",

year = "2020",

month = nov,

day = "10",

doi = "10.1182/blood.2020007150",

language = "English",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells

AU - Hanekamp, Diana

AU - Ngai, Lok Lam

AU - Janssen, Jeroen Jwm

AU - van de Loosdrecht, Arjan A

AU - Ossenkoppele, Gert J

AU - Cloos, Jacqueline

PY - 2020/11/10

Y1 - 2020/11/10

U2 - 10.1182/blood.2020007150

DO - 10.1182/blood.2020007150

M3 - Article

C2 - 33171485

JO - Blood

JF - Blood

SN - 0006-4971

ER -